Table 2.
Overall survival (OS) by site of first metastasis and mutation status.
| Site of first metastasis | Median OS (95% CI), months | 5-year OS rate (95% CI), % | p value (unadjusted)a |
|---|---|---|---|
| All patients, regardless of mutation status | |||
| All | 96 (76-119) | 62.2 (57.3-67.6) | |
| Bone only | 126 (87-NR) | 78.2 (68.6-89.0) | 0.051 |
| Bone and other | 73 (50-117) | 58.0 (48.1-69.9) | |
| Other only | 85 (59-119) | 55.0 (48.1-62.9) | |
| Patients with TP53 mutation | |||
| Bone only | 47 (32-NR) | 48.5 (24.8-94.9) | 0.487 |
| Bone and other | 67 (37-NR) | 52.4 (34.4-79.9) | |
| Other only | 59 (46-130) | 47.3 (33.4-67.0) | |
| Patients with PIK3CA mutation | |||
| Bone only | 98 (72-NR) | 86.7 (71.1-100) | 0.679 |
| Bone and other | 96 (73-NR) | 80.0 (62.1-100) | |
| Other only | 88 (53-NR) | 57.9 (43.6-76.9) | |
Abbreviations: CI, confidence interval; NR, not reached.
aFor comparison between patients with bone-only and other-only metastases.